Auryxia: Global Drug Analysis (2015-2017) with Forecasts to 2024 – ResearchAndMarkets.com

DUBLIN–()–The “Drug
Analysis: Auryxia”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii
Pharmaceutical) is a novel oral ferric iron form with hematinic
activity, approved for the treatment of anemia in chronic kidney
disease. The drug dissociates into ferric iron and citrate after
administration. Ferric iron is transported to erythroid precursor cells
to be incorporated into hemoglobin, and also binds dietary phosphate in
the gastrointestinal tract, precipitating as ferric phosphate. This
compound is excreted, decreasing the phosphate concentration in the
serum.

Key Topics Covered:

Product Profiles

Auryxia: Anemia in chronic kidney disease

List of Figures

Figure 1: Auryxia for anemia in chronic kidney disease – SWOT analysis

Figure 2: Drug assessment summary of Auryxia for anemia in chronic
kidney disease (1)

Figure 3: Drug assessment summary of Auryxia for anemia in chronic
kidney disease (2)

Figure 4: Auryxia sales for anemia in chronic kidney disease across the
US, Japan, and five major EU markets, by country, 2015-24

List of Tables

Table 1: Auryxia drug profile

Table 2: Auryxia Phase III data in anemia in chronic kidney disease

Table 3: Auryxia Phase II data in anemia in chronic kidney disease

Table 4: Auryxia sales for anemia in chronic kidney disease across the
US, Japan, and five major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ttpdw5/auryxia_global?w=4



Source link

more recommended stories

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: